{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:56:14Z","timestamp":1788350174393,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health, Labor and Welfare","award":["23AA2003"],"award-info":[{"award-number":["23AA2003"]}]},{"name":"The Ministry of Health, Labour and Welfare","award":["23AA2003"],"award-info":[{"award-number":["23AA2003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the incidence of gout in individuals with diabetes receiving metformin vs sodium\u2013glucose co-transporter-2 inhibitors (SGLT-2is).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This new-user comparative effectiveness study included adults from the JMDC claims database with health check-up and administrative claims data from 2014 to 2022. Individuals initiated on metformin were compared with those initiated on SGLT-2is. The primary outcome was the incidence of new gout diagnoses. After propensity-score inverse probability treatment weighting (IPTW), Cox proportional hazards models were fitted to estimate the hazard ratios (HRs) and 95% CIs. A linear mixed model was employed to assess the association between the two groups and changes in serum uric acid levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 21\u2009561 individuals with diabetes were identified, including 17\u2009636 males with a mean age of 53\u2009years. The metformin and SGLT-2i groups included 13\u2009535 and 8026 individuals, respectively. In the metformin and SGLT-2i groups, the gout incidence rates were 2.40 and 3.15 events per 1000 person-years, respectively. After IPTW, metformin was not associated with a decreased risk of gout compared with SGLT-2i (HR 0.90, 95% CI 0.63\u20131.28; rate difference \u20130.28, 95% CI \u20131.24 to 0.68 events per 1000 person-years). The mean difference in serum uric acid level change 1\u2009year after the index date was 0.48\u2009mg\/dl (95% CI 0.43\u20130.52) for the metformin group relative to the SGLT-2i group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Gout risk may be comparable between metformin and SGLT-2is in individuals with diabetes, with metformin showing a lesser reduction in serum uric acid levels than SGLT-2is.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf136","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T08:48:09Z","timestamp":1742719689000},"page":"4164-4171","source":"Crossref","is-referenced-by-count":3,"title":["Gout incidence in metformin versus sodium\u2013glucose co-transporter-2 inhibitor users: a retrospective cohort study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-5604","authenticated-orcid":false,"given":"Masaki","family":"Hatano","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, The University of Tokyo , Tokyo,","place":["Japan"]},{"name":"Department of Orthopaedic Surgery, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Prevention of Diabetes and Lifestyle-Related Diseases, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sasabuchi","sequence":"additional","affiliation":[{"name":"Department of Real-world Evidence, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatoshi","family":"Ishikura","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9210-9414","authenticated-orcid":false,"given":"Sakae","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"2025070205020305800_keaf136-B1","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"key":"2025070205020305800_keaf136-B2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association between gout flare and subsequent cardiovascular events among patients with gout","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"key":"2025070205020305800_keaf136-B3","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1136\/ard.2010.130013","article-title":"Impact of diabetes against the future risk of developing gout","volume":"69","author":"Rodr\u00edguez","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025070205020305800_keaf136-B4","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"2025070205020305800_keaf136-B5","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s40618-023-02162-9","article-title":"The anti-inflammatory and immunological properties of SGLT-2 inhibitors","volume":"46","author":"Bendotti","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"2025070205020305800_keaf136-B6","doi-asserted-by":"crossref","first-page":"e077097","DOI":"10.1136\/bmj-2023-077097","article-title":"Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data","volume":"385","author":"Bidulka","year":"2024","journal-title":"BMJ"},{"key":"2025070205020305800_keaf136-B7","doi-asserted-by":"crossref","first-page":"20406223221083509","DOI":"10.1177\/20406223221083509","article-title":"Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials","volume":"13","author":"Yip","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"2025070205020305800_keaf136-B8","doi-asserted-by":"crossref","first-page":"e2135353","DOI":"10.1001\/jamanetworkopen.2021.35353","article-title":"Association of sodium-glucose transport Protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan","volume":"4","author":"Chung","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025070205020305800_keaf136-B9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamainternmed.2024.0376","article-title":"Sodium-glucose Cotransporter-2 inhibitors vs sulfonylureas for gout prevention among patients with type 2 diabetes receiving metformin","volume":"184","author":"McCormick","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2025070205020305800_keaf136-B10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the risk for gout with sodium-glucose Cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"2025070205020305800_keaf136-B11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/rheumatology\/keac509","article-title":"Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes","volume":"62","author":"Zhou","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"2025070205020305800_keaf136-B12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/annrheumdis-2019-216713","article-title":"Metformin limits osteoarthritis development and progression through activation of AMPK signalling","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025070205020305800_keaf136-B13","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/rheumatology\/keac467","article-title":"Metformin attenuates osteoarthritis by targeting chondrocytes, synovial macrophages and adipocytes","volume":"62","author":"Li","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025070205020305800_keaf136-B14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-020-2129-y","article-title":"Exploration of metformin as novel therapy for osteoarthritis: preventing cartilage degeneration and reducing pain behavior","volume":"22","author":"Li","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025070205020305800_keaf136-B15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/annrheumdis-2018-214656","article-title":"mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?","volume":"78","author":"Vazirpanah","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025070205020305800_keaf136-B16","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/ard-2024-225652","article-title":"Gout risk in adults with pre-diabetes initiating metformin","volume":"83","author":"Marrugo","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025070205020305800_keaf136-B17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","article-title":"Japanese clinical practice guideline for diabetes 2019","volume":"11","author":"Araki","year":"2020","journal-title":"Diabetol Int"},{"key":"2025070205020305800_keaf136-B18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1186\/s12889-016-3602-z","article-title":"Factors associated with hospitalization for seasonal influenza in a Japanese nonelderly cohort","volume":"16","author":"Ono","year":"2016","journal-title":"BMC Public Health"},{"key":"2025070205020305800_keaf136-B19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/fampra\/cmx016","article-title":"Impact of clinic follow-up visits on body weight control in people with prediabetes or diabetes mellitus: Japanese nonelderly cohort study","volume":"34","author":"Ono","year":"2017","journal-title":"Fam Pract"},{"key":"2025070205020305800_keaf136-B20","first-page":"321","article-title":"Impact of the COVID-19 pandemic on health check-ups: a nationwide questionnaire survey in 639 healthcare facilities in Japan society of ningen dock","volume":"6","author":"Yamaguchi","year":"2023","journal-title":"JMA J"},{"key":"2025070205020305800_keaf136-B21","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pds.4044","article-title":"Validation of claims-based algorithms for gout flares","volume":"25","author":"MacFarlane","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025070205020305800_keaf136-B22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"2025070205020305800_keaf136-B23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.37737\/ace.22013","article-title":"Theory and practice of propensity score analysis","volume":"4","author":"Hashimoto","year":"2022","journal-title":"Ann Clin Epidemiol"},{"key":"2025070205020305800_keaf136-B24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/aje\/kwh175","article-title":"Imputations of missing values in practice: results from imputations of serum cholesterol in 28 cohort studies","volume":"160","author":"Barzi","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2025070205020305800_keaf136-B25","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1536867X1201200209","article-title":"Using the margins command to estimate and interpret adjusted predictions and marginal effects","volume":"12","author":"Williams","year":"2012","journal-title":"STATA J"},{"key":"2025070205020305800_keaf136-B26","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R","article-title":"Multiple imputation of missing blood pressure covariates in survival analysis","volume":"18","author":"van Buuren","year":"1999","journal-title":"Stat Med"},{"key":"2025070205020305800_keaf136-B27","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"2025070205020305800_keaf136-B28","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1136\/annrheumdis-2014-205337","article-title":"Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study","volume":"74","author":"Bruderer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025070205020305800_keaf136-B29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/dom.15310","article-title":"The effect of metformin on urate metabolism: findings from observational and Mendelian randomization analyses","volume":"26","author":"Dai","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025070205020305800_keaf136-B30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/dom.13170","article-title":"Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin","volume":"20","author":"Ouchi","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025070205020305800_keaf136-B31","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/annrheumdis-2021-220439","article-title":"Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan","volume":"80","author":"Koto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025070205020305800_keaf136-B32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.clinthera.2024.06.021","article-title":"SGLT2 inhibitors, but not GLP-1 receptor agonists, reduce incidence of gout in people living with type 2 diabetes across the therapeutic spectrum","volume":"46","author":"Preston","year":"2024","journal-title":"Clin Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf136\/62574842\/keaf136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4164\/62574842\/keaf136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4164\/62574842\/keaf136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:02:14Z","timestamp":1751432534000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/7\/4164\/8092567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,3,24]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf136","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,24]]}}}